title: Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.
abstract: Eltrombopag (SB-497 115) is a first-in-class, oral, small-molecule, nonpeptide agonist of the thrombopoietin receptor (TpoR), being developed as a treatment for thrombocytopenia of various etiologies. In this phase 1 placebo-controlled clinical trial in 73 healthy male subjects, eltrombopag was administered as once-daily oral capsules for 10 days at doses of 5, 10, 25, 30, 50, and 75 mg. The pharmacokinetics of eltrombopag were dose dependent and linear, and eltrombopag increased platelet counts in a dose-dependent manner. There were no apparent differences in the incidence or severity of adverse events in subjects receiving active or placebo study medication. These observations indicate that eltrombopag is a once-daily, oral TpoR agonist with demonstrated thrombopoietic activity in human subjects, encouraging further studies in patients with thrombocytopenia.
authors.affiliation: GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426, USA. julian.m.jenkins@gsk.com
authors.forename: Julian M
authors.initials: JM
authors.lastname: Jenkins
authors.forename: Daphne
authors.initials: D
authors.lastname: Williams
authors.forename: Yanli
authors.initials: Y
authors.lastname: Deng
authors.forename: Joanne
authors.initials: J
authors.lastname: Uhl
authors.forename: Valerie
authors.initials: V
authors.lastname: Kitchen
authors.forename: David
authors.initials: D
authors.lastname: Collins
authors.forename: Connie L
authors.initials: CL
authors.lastname: Erickson-Miller
mesh_terms: D000284:Administration, Oral; D000328:Adult; D001565:Benzoates / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D001792:Blood Platelets / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D006834:Hydrazines / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D008297:Male; D010919:Placebos; D010976:Platelet Count; D011720:Pyrazoles / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D053628:Receptors, Thrombopoietin / Q000819:agonists*; D013921:Thrombocytopenia / Q000188:drug therapy*; D034061:Thrombopoiesis; D013997:Time Factors
chemical_list: D001565:Benzoates; D006834:Hydrazines; D010919:Placebos; D011720:Pyrazoles; D053628:Receptors, Thrombopoietin; C520809:eltrombopag